Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
We aim to support specific project requirements by providing researchers access to high-quality, scientifically validated formulations
R-Alpha Lipoic Acid 600mg, Antioxidant, 30 Capsules R-Alpha Lipoic Acid 600mg, Antioxidant, 60 Capsules is a dietary supplement
This can improve acne marks and overall skin texture over time
CAGRILINTIDE'S SPECIFIC EFFECTS ON APPETITE PHYSIOLOGY REDUCED APPETITE RATINGS AND FOOD CRAVINGS Research participants and study data consistently document reduced appetite as measured by hunger scales and appetite questionnaires
